BMJ Open publishes all reviews undertaken for accepted manuscripts. Reviewers are asked to complete a checklist review form (http://bmjopen.bmj.com/site/about/resources/checklist.pdf) and are provided with free text boxes to elaborate on their assessment. These free text comments are reproduced below.
METHODS
• Please state if the Registry enrol consecutive patients • Please state if the Registry does undergo any audits, or if events are externally adjudicated • Please state how the Registry managed new evolving standardized definitions such as VARC and VARC-2 (reported) with old patients prior to the VARC and VARC-2 era. Especially difficult to manage are, for example, acute kidney injury definitions. Were the endpointsre-adjudicated for this paper? RESULTS • It would be of interest to frame the Registry within European and German Registries, it is surely a high volume center, but… how high? Can you provide numbers of SAVR procedures on your center in the same timeframes to compare TAVR evolution against SAVR?
• Please describe general approach to TAVR. Was TF procedures performed with vascular surgery or purely percutaneous? General Anesthesia or deep sedation? Please describe also how is composed the TAVR Team. Interventional Cardiologist only for TF and Cardiac surgeons only for TA? Mixed teams?
• Have the authors considered, beyond pure chronologic division of the cohorts, to compare the patients through first, second and third generation of the devices (Edwards Sapien+Corevalve, Edwards Sapien XT+Corevalve Evolut, Sapien 3+Corevalve Evolut R). This would add considerable interest, at least as a subanalyses. Chronologic division of the cohorts does not especially make sense (is patient 499 different from 501?) beyond showing the learning curve of the operators (which is due largely in the first 500 patients) and some perspective on the technique.
• The chronologic division of the Registry makes probably some random statistical findings such as the increase in renal failure on cohort III, or an increase on stroke in cohort IV.
• Could the increase on stroke in cohort IV be associated to changes in DAPT or post-TAVR antithrombotic medications? Please comment on this issue.
• Please show in table 2 numbers of Corevalve, CV Evolut, and CV Evolut R • Frailty, functional impairment and surgical risk decreased considerably over time. Can the authors provide number on patients discarded for any invasive therapy? Did theses numbers increase as well over time? DISCUSSION • Page 13, line 36. Please futher explain the sentence "However, the numbers of patients undergoing TAVI via the transaortic (TAo) and subclavian routes were not systematically recorded in the present analysis. " Was or was not the enrolment of AS patients undergoing TAVR consecutive? Which number or % of lost patients might this represent (at least, approximately) • It's surprising not to find improvement in device success within the last cohort, given the great results of Corevalve Evolut R and Sapien 3 regarding paravalvular AR and smaller delivery sistems. Please comment on this, it's not probably due to learning curve as commented in page 14, line 11. The whole paragraph praises the technical improvements but lacks of adequate discussion on how this was not translated into outcomes from cohort III to IV, where a majority of TAVR were Sapien 3. You comment on small annulus referencing a paper but not explaining if this happened in the study population.
• Might this lack of improved outcomes be due to a wider range of operators performing TAVR instead of a few operators leading first cases? Could you briefly comment in the paper how the widespreading of the procedure was managed within the interventional cardiology staff team?
• "Nevertheless, it is possible that the small number of patients with 1-year follow-up in cohort IV may have limited the statistical power to detect such differences." The IV cohort ended in 2015…why were not all patients followed until 1 year? CONCLUSIONS • I would recommend a complete rephrasing of the conclusions:
• If lower risk patients are more able to benefit for TAVR or not is not a fair conclusion of this study. The population profile of this registry does not support nor preclude benefit for TAVR in any specific subset • The registry shows some not-so-optimistic findings such as unimproved 1-year mortality, lack of improvement in device success in the latter cohorts. This should be somehow reflected in the conclusions • "However, a continuation of physician education alongside technique refinement is required before the full potential of TAVI can be realised. Studies regarding long-term clinical outcomes and prosthesis durability would be insightful." Those are nice reflexions on TAVR, but they does not have any relationship with the Registry 
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